Stay updated on KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.

Latest updates to the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe revision tag on the page history updated from v3.5.2 to v3.5.3, indicating a new release of the page's history metadata.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the record history. This reflects a version change in the page’s interface rather than substantive trial data.SummaryDifference0.1%

- Check43 days agoChange DetectedThe sponsor field was updated from 'Karuna Therapeutics' to 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company' to reflect the full corporate affiliation.SummaryDifference0.2%

- Check57 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed in the Record History.SummaryDifference0.1%

- Check64 days agoChange DetectedA new revision entry v3.4.3 was added and the v3.4.2 entry was removed from the page history.SummaryDifference0.1%

- Check93 days agoChange DetectedAdded Revision: v3.4.2 to the history, marking a new release in the study record's version list. Removed the older funding-status notice and Revision: v3.4.1 from the history view.SummaryDifference0.6%

Stay in the know with updates to KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.